Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2026-11 · 26 (11) · 768-780.e5
DOI: 10.1016/j.clml.2026.08.019 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Gurdeep Parmar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Illawarra Cancer Care Centre, Wollongong Hospital, University of Wollongong, Wollongong, New South Wales, Australia. Electronic address: Gurdeep.Parm…. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Reported Outcome Measures, Antibodies, Monoclonal, Humanized, Health Personnel. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi-Aventis US LLC.
Abstract (Originalsprache)
BACKGROUND: The phase 2 IZALCO study (NCT05704049) demonstrated comparable efficacy, safety, and pharmacokinetics for subcutaneous (SC) isatuximab administered via an on-body injector (Isa SC OBI) versus manual injection in combination with carfilzomib-dexamethasone in relapsed/refractory multiple myeloma. PATIENTS AND METHODS: We evaluated patient-reported outcomes (PROs) in 74 adults and experiences of 19 healthcare providers (HCPs) from IZALCO. In part 1, Isa was given via manual injection. In part 2, patients were randomly assigned to manual injection or Isa SC OBI in cycle (C)1-3 and crossed over to the other method for C4-6. From C7, patients could select either method. Patient preference of delivery method at C6 Day (D)15 was a key secondary endpoint (n = 47). PROs and HCP experience were assessed using the Patient Expectations Questionnaire, Patient Experience and Satisfaction Questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and HCP questionnaire. RESULTS: In part 2, at C6D15, after experiencing both methods, 74.5% (35/47) of patients preferred Isa SC OBI over manual injection, with comfort, convenience, and reduced injection-site pain being the main reasons for preference. Fewer patients reported discomfort, pain, and side effects with Isa SC OBI versus manual injection at most time points. Most patients (90.4%, 47/52) opted for Isa SC OBI from C7 onward. Mean EORTC QLQ-C30 global health status/QoL score was maintained over time. Of 19 HCPs, 78.9% (15/19) preferred Isa SC OBI versus manual injection. CONCLUSION: These findings support Isa SC OBI as the preferred administration method for patients and HCPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Illawarra Cancer Care Centre, Wollongong Hospital, University of Wollongong, Wollongong, New South Wales, Australia. Electronic address: Gurdeep.Parmar@health.nsw.gov.au.
- Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
- Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil.
- Hematologia e Hemoterapia do Hospital das Clinicas - FMUSP, São Paulo, Brazil.
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea.
- Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos General Hospital, Athens, Greece.
Förderung
- Sanofi-Aventis US LLC
Zitieren
APA
Parmar, G., Capra, M., Hungria, V., Seguro, F. S., Dimopoulos, M. A., Delimpasi, S., Špička, I., Minařík, J., Marques, H., Pour, L., Mihályová, J., Yuda, J., Sunami, K., Esteves, G., Chmielewski, C., Soufflet, C., Yu, D., Comerford, E., Suzan, F., …, & Quach, H. (2026). Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26(11), 768-780.e5. https://doi.org/10.1016/j.clml.2026.08.019
Vancouver
Parmar G, Capra M, Hungria V, Seguro FS, Dimopoulos MA, Delimpasi S, et al. Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026;26(11):768-780.e5. doi:10.1016/j.clml.2026.08.019
BibTeX
@article{Parmar2026,
author = {Parmar, Gurdeep and Capra, Marcelo and Hungria, Vania and Seguro, Fernanda Salles and Dimopoulos, Meletios-Athanasios and Delimpasi, Sosana and Špička, Ivan and Minařík, Jiří and Marques, Herlander and Pour, Ludĕk and Mihályová, Jana and Yuda, Junichiro and Sunami, Kazutaka and Esteves, Graça and Chmielewski, Cynthia and Soufflet, Christine and Yu, Disa and Comerford, Erin and Suzan, Florence and Cordero, Paul and Zhang, Rick and Quach, Hang},
title = {Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {11},
pages = {768--780.e5},
doi = {10.1016/j.clml.2026.08.019}
}
EUVIMED